Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping

Psychopharmacology

Volumn 188, Issue 4, 2006, Pages 629-640

  Lindner, Mark D ^a   Hogan, John B ^a   Hodges Jr , Donald B ^a   Orie, Anitra F ^a   Chen, Ping ^a   Corsa, Jason A ^a   Leet, John E ^a   Gillman, Kevin W ^a   Rose, Gregory M ^a   Jones, Kelli M ^a   Gribkoff, Valentin K ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

5 Choice serial reaction time testing; Acetylcholinesterase inhibitors; Delayed nonmatching to position; Fear conditioning; Morris water maze; Radial arm maze

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; SCOPOLAMINE; INDAN DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; PIPERIDINE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; CHOLINERGIC SYSTEM; COGNITION; CONDITIONING; CONTROLLED STUDY; DRUG EFFECT; FEAR; MALE; MAZE TEST; MEMORY DISORDER; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; PSYCHOMOTOR DISORDER; RAT; REACTION TIME; SPATIAL MEMORY; WORKING MEMORY; ANIMAL; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT; MEMORY; SPRAGUE DAWLEY RAT;

ANIMALS; ATTENTION; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; CONDITIONING (PSYCHOLOGY); INDANS; MALE; MAZE LEARNING; MEMORY; MUSCARINIC ANTAGONISTS; PIPERIDINES; PSYCHOMOTOR DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; SCOPOLAMINE;

EID: 34248525381     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0556-3     Document Type: Article

References (41)

1. Bontempi B, Whelan KT, Risbrough VB, Lloyd GK, Menzaghi F (2003) Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors. Neuropsychopharmacology 28:1235-1246
2. Borkowska A, Ziolkowska-Kochan M, Rybakowski JK (2005) Oneyear treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests. Hum Psychopharmacol 20:409-414
3. Braida D, Paladini E, Griffini P, Lamperti M, Maggi A, Sala M (1996) An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. Eur J Pharmacol 302:13-20
4. Broks P, Preston GC, Traub M, Poppleton P, Ward C, Stahl SM (1988) Modelling dementia: effects of scopolamine on memory and attention. Neuropsychologia 26:685-700
5. Bucks RS, Ashworth DL, Wilcock GK, Siegfried K (1996) Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing 25:113-120
6. Chen Z, Xu AJ, Li R, Wei EQ (2002) Reversal of scopolamine-induced spatial memory deficits in rats by TAK-1471. Acta Pharmacol Sin 23:355-360
7. Cheng DH, Ren H, Tang XC (1996) Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport 8:97-101
8. Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Lawrence Erlbaum, Hillsdale, New Jersey
9. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P (2004) Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363:2105-2115
10. Dawson GR, Iversen SD (1993) The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. Behav Brain Res 57:143-153
11. Dooley M, Lamb HM (2000) Donepezil: a review of its use in Alzheimer's disease. Drugs Aging 16:199-226
12. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198
13. Gallagher M, Burwell R, Burchinal M (1993) Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris water maze. Behav Neurosci 107:618-626
14. Hamann S, Monarch ES, Goldstein FC (2002) Impaired fear conditioning in Alzheimer's disease. Neuropsychologia 40:1187-1195
15. Higgins GA, Enderlin M, Fimbel R, Haman M, Grottick AJ, Soriano M, Richards JG, Kemp JA, Gill R (2002) Donepezil reverses a mnemonic deficit produced by scopolamine but not by perforant path lesion or transient cerebral ischaemia. Eur J Neurosci 15:1827-1840
16. Hutchison CW, Nathan PJ, Mrazek L, Stough C (2001) Cholinergic modulation of speed of early information processing: the effect of donepezil on inspection time. Psychopharmacology (Berl) 155:440-442
17. Jones DN, Higgins GA (1995) Effect of scopolamine on visual attention in rats. Psychopharmacology (Berl) 120:142-149
18. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H (2005) Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 331:321-327
19. Kirkby DL, Jones DN, Barnes JC, Higgins GA (1996) Effects of anticholinesterase drugs tacrine and E2020, the 5-HT(3) antagonist ondansetron, and the H(3) antagonist thioperamide, in models of cognition and cholinergic function. Behav Pharmacol 7:513-525
20. Kluger A, Gianutsos JG, Golomb J, Ferris SH, George AE, Franssen E, Reisberg B (1997a) Patterns of motor impairment in normal aging, mild cognitive decline, and early Alzheimer's disease. J Gerontol B Psychol Sci Soc Sci 52:28-39
21. Kluger A, Gianutsos JG, Golomb J, Ferris SH, Reisberg B (1997b) Motor/psychomotor dysfunction in normal aging, mild cognitive decline, and early Alzheimer's disease: diagnostic and differential diagnostic features. Int Psychogeriatr 9:307-316
22. Kmietowicz Z (2005) NICE proposes to withdraw Alzheimer's drugs from NHS. BMJ 330:495
23. Lawrence AD, Sahakian BJ (1995) Alzheimer disease, attention, and the cholinergic system. Alzheimer Dis Assoc Disord 9:43-49
24. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34:939-944
25. Muller G, Richter RA, Weisbrod S, Klingberg F (1991) Reaction time prolongation in the early stage of presenile onset Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 241:46-48
26. National Research Council (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington, DC
27. Ogura H, Kosasa T, Kuriya Y, Yamanishi Y (2000) Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats. Methods Find Exp Clin Pharmacol 22:89-95
28. Perry EK, Perry RH, Gibson PH, Blessed G, Tomlinson BE (1977) A cholinergic connection between normal aging and senile dementia in the human hippocampus. Neurosci Lett 6:85-89
29. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 2:1457-1459
30. Peters BH, Levin HS (1979) Effects of physostigmine and lecithin on memory in Alzheimer disease. Ann Neurol 6:219-221
31. Poorheidari G, Stanhope KJ, Pratt JA (1998) Effects of the potassium channel blockers, apamin and 4-aminopyridine, on scopolamine-induced deficits in the delayed matching to position task in rats: a comparison with the cholinesterase inhibitor E2020. Psychopharmacology (Berl) 135:242-255
32. Robbins TW (2002) The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl) 163:362-380
33. SAS Institute (1999) SAS/STAT user's guide, Version 8. SAS Institute, Cary, North Carolina
34. Sinson G, Voddi M, McIntosh TK (1995) Nerve growth factor administration attenuates cognitive but not neurobehavioral motor dysfunction or hippocampal cell loss following fluid-percussion brain injury in rats. J Neurochem 65:2209-2216
35. Smith CM, Swash M (1978) Possible biochemical basis of memory disorder in Alzheimer disease. Ann Neurol 3:471-473
36. Sunderland T, Tariot PN, Weingartner H, Murphy DL, Newhouse PA, Mueller EA, Cohen RM (1986) Pharmacologic modelling of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 10:599-610
37. Tokita K, Yamazaki S, Yamazaki M, Matsuoka N, Mutoh S (2002) Combination of a novel antidementia drug FK960 with donepezil synergistically improves memory deficits in rats. Pharmacol Biochem Behav 73:511-519
38. Wang T, Tang XC (1998) Reversal of scopolamine-induced deficits in radial maze performance by (?)-huperzine A: comparison with E2020 and tacrine. Eur J Pharmacol 349:137-142
39. Yamaguchi Y, Higashi M, Matsuno T, Kawashima S (2001) Ameliorative effects of azaindolizinone derivative ZSET845 on scopolamine-induced deficits in passive avoidance and radial-arm maze learning in the rat. Jpn J Pharmacol 87:240-244
40. Zec RF, Landreth ES, Vicari SK, Belman J, Feldman E, Andrise A, Robbs R, Becker R, Kumar V (1992a) Alzheimer disease assessment scale: a subtest analysis. Alzheimer Dis Assoc Disord 6:164-181
41. Zec RF, Landreth ES, Vicari SK, Feldman E, Belman J, Andrise A, Robbs R, Kumar V, Becker R (1992b) Alzheimer disease assessment scale: useful for both early detection and staging of dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 6:89-102